Meta-analyses indicate that GLP-1 RAs lower both systolic and diastolic blood pressure and improve lipid profiles in obese patients without T2DM, thereby reducing cardiovascular risk [74,75]. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.